ACR 2025: Phase 3 Telitacicept Results in Sjögren’s Disease
Boston, September 29, 2025 Vor Bio has announced that late-breaking Phase 3 clinical data of telitacicept in primary Sjögren’s...
telitacicept
Advertisement
Advertisement
Advertisement
Boston, September 29, 2025 Vor Bio has announced that late-breaking Phase 3 clinical data of telitacicept in primary Sjögren’s...
Advertisement